InvestorsHub Logo
Followers 30
Posts 4083
Boards Moderated 0
Alias Born 07/25/2007

Re: biocqr post# 2388

Wednesday, 12/21/2022 11:59:15 AM

Wednesday, December 21, 2022 11:59:15 AM

Post# of 2958

Thanks. How concerning is the possibility of protease mutations that would diminish EDP-235 efficacy?



We can worry about this after EDP-235 has been approved and garnered $20 billion in sales in the first year or two. :)

Even if some resistance is generated to Paxlovid, EDP-235 is a different molecule based on patent filings making it less likely to have cross-resistance.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News